SEER Inquiry System - Home

Solid Tumor Rules/Multiple primaries--Breast:  How many primaries should be abstracted when papillary carcinoma is identified in two biopsies and a subsequent lumpectomy identified invasive ductal carcinoma with multifocal ductal carcinoma in situ (DCIS)?  See Discussion.

Solid Tumor Rules (2018)/Histology--Cervix uteri:  What is the correct histology code for malignant mixed Mullerian tumor (MMMT/Carcinosarcoma)?  See Discussion.

Solid Tumor Rules (2018)/Histology--Lung:  The Histology coding guidelines for lung cancer state to code histology when stated as type or subtype but not to code when described as pattern. How should the histology be coded (Adeno, NOS or Adeno, Mixed subtypes) if the College of Americal Pathologists Protocol of the pathology report lists the following: Histologic type: Adenocarcinoma, papillary (90%), lepidic (8%), and solid (2%) patterns?

Immunotherapy:  Is immunotherapy ever palliative treatment according to any oncologists or SEER?

Solid Tumor Rules (2018)/Recurrence--Breast:  Does any recurrence within the multiple primaries-stated timeframe count, not those just in the primary site?  See Discussion.

Histology--Heme & Lymphoid Neoplasms: How is histology coded when a lymph node excisional biopsy shows Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), predominantly in diffuse T-cell histiocyte rich large B-cell lymphoma-like (THRLBCL) pattern.  Comment states: The findings are that of nodular lymphocyte predominant Hodgkin lymphoma with diffuse T-cell rich pattern (T-cell/histiocyte-rich large B-cell lymphoma-like). This variant is regarded as clinically more advanced. See Discussion.

Primary Site:  How should primary site be coded when there is an invasive tumor in one subsite and an in situ tumor in another subsite of the breast?  See Discussion.

Primary Site--Ovary:  How should primary site be coded for a previously diagnosed ovarian cancer which is now being reclassified as fallopian tube?  See Discussion.

Reportability/Heme & Lymphoid Neoplasms: Is monoclonal B-cell lymphocytosis reportable? See Discussion.

 

EOD 2018/Summary Stage 2018--Head & Neck: When the reportable suspicious cytology used to code diagnosis date is a regional lymph node fine needle aspirate (FNA), should this information also be used to code positive Extent of Disease (EOD) Regional Nodes, Regional Nodes Positive, Regional Nodes Examined, and SEER Summary Stage 2018?  See Discussion.